Diagnosis and Treatment > Medication

You are looking at 31 - 32 of 32 items for :

  • Testosterone x
Clear All
Pia T Dinesen Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Pia T Dinesen in
Google Scholar
PubMed
Close
,
Jakob Dal Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Jakob Dal in
Google Scholar
PubMed
Close
,
Plamena Gabrovska Department of Endocrinology, Bart's and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by Plamena Gabrovska in
Google Scholar
PubMed
Close
,
Mette Gaustadnes Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Mette Gaustadnes in
Google Scholar
PubMed
Close
,
Claus H Gravholt Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Claus H Gravholt in
Google Scholar
PubMed
Close
,
Karen Stals Department of Molecular Genetics, Royal Devon and Exeter, Foundation Trust, Exeter, UK

Search for other papers by Karen Stals in
Google Scholar
PubMed
Close
,
Judit Denes Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Judit Denes in
Google Scholar
PubMed
Close
,
Sylvia L Asa Department of Pathology, University Health Network, Toronto, Ontario, Canada
Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada

Search for other papers by Sylvia L Asa in
Google Scholar
PubMed
Close
,
Márta Korbonits Department of Endocrinology, Bart's and the London School of Medicine, Queen Mary University of London, London, UK

Search for other papers by Márta Korbonits in
Google Scholar
PubMed
Close
, and
Jens O L Jørgensen Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark

Search for other papers by Jens O L Jørgensen in
Google Scholar
PubMed
Close

Summary

A patient of Cushing's disease (CD) characterized by a large tumor and only subtle symptoms of hormonal hypersecretion was examined. The patient had a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene. A 50-year-old male presenting with headache was diagnosed with a large pituitary tumor by magnetic resonance imaging (MRI). His visual fields were intact and he exhibited no features of CD. Owing to an exuberant response to synacthen, an overnight dexamethasone suppression test was performed revealing inadequate suppression of plasma cortisol (419 nmol/l). Owing to tumor growth and visual field impairment, he underwent transsphenoidal surgery and developed hypocortisolemia. The pathology specimen revealed a sparsely granulated corticotrope adenoma. Postoperative MRI showed a large tumor remnant. The patient developed skin hyperpigmentation and a synacthen test demonstrated high basal and stimulated cortisol levels; an overnight dexamethasone suppression test showed no suppression (791 nmol/l) and elevated plasma ACTH levels (135 ng/l). A transcranial operation was performed followed by radiotherapy. Two months after radiotherapy, he developed secondary adrenocortical failure. Genetic testing revealed an AIP variant of unknown significance (p.R16H) without loss of the normal AIP allele in the tumor. A literature review showed ten CD patients with AIP gene variants, of whom five (including our case) were p.R16H. CD is occasionally dominated by pituitary tumor growth rather than symptoms of hypersecretion. The particular AIP gene variant identified in our patient is shared by four other reported cases of CD. Future studies are needed to assess whether the reported AIP gene variant is more than just coincidental.

Learning points

  • CD is occasionally dominated by pituitary tumor growth rather than symptoms of hypersecretion.

  • Resolution of both tumor remnant and hormonal hypersecretion may occur within 2 months after postoperative radiotherapy.

  • The particular AIP gene variant identified in our patient is shared by four other reported cases of CD.

Open access
Jaya Sujatha Gopal-Kothandapani Department of Human Metabolism, University of Sheffield, Sheffield, UK

Search for other papers by Jaya Sujatha Gopal-Kothandapani in
Google Scholar
PubMed
Close
,
Veejay Bagga Department of Neurosurgery, Royal Hallamshire Hospital, Sheffield, UK

Search for other papers by Veejay Bagga in
Google Scholar
PubMed
Close
,
Stephen B Wharton Department of Histopathology, Royal Hallamshire Hospital, Sheffield, UK

Search for other papers by Stephen B Wharton in
Google Scholar
PubMed
Close
,
Daniel J Connolly Department of Neuroradiology, Royal Hallamshire Hospital, Sheffield, UK
Department of Neuroradiology, Sheffield Children's Hospital, Sheffield, S10 2TH, UK

Search for other papers by Daniel J Connolly in
Google Scholar
PubMed
Close
,
Saurabh Sinha Department of Neurosurgery, Royal Hallamshire Hospital, Sheffield, UK
Department of Neurosurgery, Sheffield Children's Hospital, Sheffield, S10 2TH, UK

Search for other papers by Saurabh Sinha in
Google Scholar
PubMed
Close
, and
Paul J Dimitri Department of Paediatric Endocrinology, Sheffield Children's Hospital, Sheffield, S10 2TH, UK

Search for other papers by Paul J Dimitri in
Google Scholar
PubMed
Close

Summary

Xanthogranulomatous hypophysitis (XGH) is a very rare form of pituitary hypophysitis that may present both clinically and radiologically as a neoplastic lesion. It may either be primary with an autoimmune aetiology and can occur in isolation or as a part of autoimmune systemic disease or secondary as a reactive degenerative response to an epithelial lesion (e.g. craniopharyngioma (CP), Rathke's cleft cyst, germinoma and pituitary adenomas) or as a part of a multiorgan systemic involvement such as tuberculosis, sarcoidosis or granulomatosis. It may also present with a variation of symptoms in children and adults. Our case series compares the paediatric and adult presentations of XGH and the differential diagnoses considered in one child and two adult patients, highlighting the wide spectrum of this condition. Endocrine investigations suggested panhypopituitarism in all three patients and imaging revealed a suprasellar mass compressing the optic chiasm suggestive of CP or Rathke's cleft cyst in one patient and non-functioning pituitary macroadenoma in two patients. Magnetic resonance imaging (MRI) demonstrated mixed signal intensities on T1- and T2-weighted sequences. Following endoscopic transsphenoidal surgery, histological analysis revealed necrotic material with a xanthogranulomatous reaction confirming XGH in two patients and a necrobiotic granulomatous chronic inflammatory infiltrate with neutrophils in one patient, which is not typical of current descriptions of this disorder. This case series describes the wide spectrum of XGH disease that is yet to be defined. Mixed signal intensities on T1- and T2-weighted MRI sequences may indicate XGH and diagnosis is confirmed by histology. Histological variation may indicate an underlying systemic process.

Learning points

  • XGH is a rare form of pituitary hypophysitis with a wide clinical and histological spectrum and can mimic a neoplastic lesion.

  • XGH primarily presents with growth arrest in children and pubertal arrest in adolescents. In adults, the presentation may vary.

  • A combination of hypopituitarism and mixed signal intensity lesion on MRI is suggestive of XGH and should be considered in the differential diagnosis of sellar lesions.

  • Radical surgery is the treatment of choice and carries an excellent prognosis with no recurrence.

Open access